New Challenges for the Advanced Practitioner for Optimal Patient Education


Program Dates: July 15th, 2021 - July 14th, 2022
Credits: 0.50 AMA PRA Category 1 Credits™ and 0.50 CNE Contact Hours


New Challenges for the Advanced Practitioner for Optimal Patient Education

Program Overview

In this module, Jamie Faber, PA-C, along with Scott Kopetz, MD, PhD, course chair, will first delve into the practical considerations of biomarker testing for the interprofessional team. The expert faculty will also provide an overview of ctDNA, including the clinical implications in the colorectal cancer landscape. Following, best practices for managing adverse events to improve patient outcomes will be relayed. Upon completion of this 30-minute module, clinicans will be equipped with current, team-based techniques for providing comprehensive care and improving patient quality of life.

Target Audience

Community oncologists, oncologists, advanced practitioners, oncology nurses, and other healthcare professionals involved in the care of patients with colorectal cancer

Learning Objectives

  1. Highlight current challenges for the advanced practitioner in delivering optimal patient education

Chair

Scott Kopetz, MD, PhD
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

 

Faculty

Jamie Marie Faber, PA-C
University of Texas MD Anderson Cancer Center
Houston, Texas

 

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Scott Kopetz, MD, PhD

 

Consultant/Advisor: Amal Therapeutics; Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer Health; Biocartis; Boehringer Ingelheim International GmbH; Boston Biomedical; EMD Serono, Inc.; Eli Lilly and Company; Genentech, Inc.; Holy Stone Healthcare Co., Ltd.; Karyopharm Therapeutics; Medimmune, LLC; Merck & Co.; Navire Pharma, Inc.; Novartis AG; Pierre Fabre; Redx Pharma; Roche; Symphogen
Jamie Marie Faber, PA-C

 

Nothing to disclose  

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AcademicCME designates this live material for a maximum of 0.50 AMA PRA Category 1 Credits TM.

AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours, including 0.50 Pharmacotherapeutic Contact Hours (Provider Number P0491).

Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Pfizer Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Pfizer Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

Provided by: AcademicCME-web